Introduction {#sec1_1}
============

Solitary fibrous tumors (SFTs) are rare, benign, spindle-cell tumors of mesenchymal origin that generally develop in adults. SFTs of the orbit have been diagnosed with increasing frequency in recent years as the result of widespread use of immunohistochemistry, although rare. SFTs arise in many locations of the orbital soft tissues, but commonly involve the superior area \[[@B1]\]. Since Scott et al. \[[@B2]\] first reported SFT in the lacrimal gland fossa in 1996, there have only been 9 reported cases in the lacrimal gland fossa (table [1](#T1){ref-type="table"}) \[[@B1], [@B2], [@B3], [@B4], [@B5], [@B6], [@B7]\]. We report a case of SFT in the lacrimal gland fossa presenting at a young age, including features of imaging, histological and immunohistochemical studies.

Case Report {#sec1_2}
===========

A 25-year-old woman presented with a painless palpable mass in the left upper eyelid accompanied by mild proptosis (fig. [1](#F1){ref-type="fig"}). The mass was mobile, hard, smooth, nontender and well delineated. It increased in size for 6 months, reaching approximately 15 mm in diameter. Computed tomography showed a homogenous isodense ovoid mass with distinct margins without bone invasion in the lacrimal gland fossa (fig. [2](#F2){ref-type="fig"}). T1- and T2-weighted magnetic resonance imaging showed a high-intensity mass with various low-intensity areas, encapsulated by a low-intensity 1-mm thick capsule (fig. [2](#F2){ref-type="fig"}). The preoperative diagnosis was lacrimal gland tumor or deep dermoid cyst.

The patient underwent tumor excision via upper eyelid crease approach. A smooth, encapsulated mass was identified beneath the swollen lacrimal gland (fig. [3](#F3){ref-type="fig"}). The tumor was not attached to the periosteum and was completely removed. Postoperatively, there was noted improvement of proptosis. At the time of last examination, 6 months after surgery, no evidence of recurrence was observed.

Postoperative histopathology revealed bipolar oval to spindle-shaped cells in a heavily collagenized stroma, with focal accumulation of macrophages (fig. [4a, b](#F4){ref-type="fig"}). No necrosis was present. Immunohistochemical findings supported the diagnosis of SFT. Tumor cells were positive for the cluster of differentiation 34 (CD34), signal transducer and activator of transcription 6 (STAT6), S-100, B-cell leukemia-2 (BCL-2), CD99 and α-smooth muscle actin (SMA), but negative for desmin, epithelial membrane antigen (EMA) and cytokeratin (fig. [4c, d](#F4){ref-type="fig"}). MIB-1 was present in 10% of all cells.

Discussion {#sec1_3}
==========

We present the rare case of a 25-year-old woman with orbital SFT in the lacrimal gland fossa. The lacrimal gland ducts and acini are of epithelial origin, but not the main/palpebral lobes of the lacrimal gland. SFT therefore likely arises from periductal connective tissue or from other mesenchymal elements in the lacrimal gland fossa, with subsequent tumor growth around the lacrimal gland ducts and acini \[[@B2]\]. There is no apparent gender predilection for this tumor.

Orbital SFT rarely occurs at a young age \[[@B3]\], but generally develops in the fifth to seventh decade of life. SFT in the lacrimal gland fossa has a preponderance in the third decade of life, including this case (table [1](#T1){ref-type="table"}). SFT must therefore be considered in lacrimal gland fossa tumors presenting in young adults.

The clinical presentation of orbital SFT in the lacrimal gland fossa is similar to other lacrimal gland tumors with a slow-growing painless palpable mass, but less commonly with ptosis, eyelid swelling and diplopia (table [1](#T1){ref-type="table"}). SFT must therefore be listed in the differential diagnoses for lacrimal gland tumors in the younger age group. Deep dermoids also comprise another differentiation with these symptoms and age \[[@B8]\].

The reported radiological appearances of SFT are nonspecific. This tumor usually shows a well-defined mass, which is isointense on T1-weighted images and isointense to hypointense on T2-weighted images, reflecting fibrous tissue with high collagen content. Hyperintense areas are occasionally seen within the lesion on T2-weighted images, as shown in the present case. Variations of the signal intensity on T2-weighted magnetic resonance images likely reflect differences in the amount of cellular components, collagen, and fibroblasts as well as in the extent of degenerative change contained in the individual tumors \[[@B9]\].

Histologically, SFTs are difficult to differentiate from other spindle cell tumors. In this case, the findings showed spindle-shaped cells in heavily collagenized stroma. Fibrous histiocytoma, hemangiopericytoma, and giant cell angiofibroma, however, also present in a similar fashion. Immunohistochemistry is needed to confirm the diagnosis of SFT.

Immunohistochemically, SFTs commonly show positivity for CD34 (80--90% of cases), CD99 (70%), BCL-2 (30%), EMA (30%) and SMA (20%), but negativity for S-100, desmin and cytokeratin \[[@B10]\]. However, these markers are currently known to be nonspecific, resulting in many exceptions. For example, CD34, CD99, BCL-2 and SMA were positive, but S-100 was unusually positive in the present case. Since there were contradictory results for the aforementioned markers, further staining with STAT6 confirmed the definitive diagnosis. More recently, demonstration of strong nuclear expression of the C-terminal of STAT6 has been shown to be a highly sensitive and specific marker for SFT, with an aggregate sensitivity of 98% and a specificity \>85% \[[@B11]\].

Complete resection is the single most important determinant for the prognosis of SFTs. There is no conclusive evidence that radiotherapy or chemotherapy provide any benefits in cases of residual tumors. Hence, these tumors may need further surgical excision, and regular follow-up is essential. In this case, the encapsulated nature of the tumor allowed total excision, resulting in no recurrence following surgery.

Although rare, orbital SFTs show malignant progression \[[@B12]\]. Risk factors for a malignant potential include presence of histological malignant component, with increased cellularity and mitoses, positive surgical margins, and tumor size \>10 cm \[[@B13]\]. No histological malignancy, total excision, and tumor size \<10 cm in this patient were associated with little risk of future recurrence with malignant progression.

In summary, SFT must be considered in lacrimal gland fossa tumors presenting in young adults. They are rare tumors of mesenchymal origin for which positive staining for STAT6 is the most specific diagnostic test. They generally follow a benign course and are treated definitively with surgical excision.
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![Preoperative face photograph. A hard, smooth, well-delineated mass (15 mm in diameter) is shown (arrow).](cop-0007-0398-g01){#F1}

![Findings of imaging studies. **a**, **b** Computed tomography showed a homogenous isodense round to ovoid lesion with distinct margins without bone invasion in the extraconal superolateral orbit (arrows). **c**, **d** T1- and T2-weighted magnetic resonance imaging showed a high-intensity mass with contents of various intensity.](cop-0007-0398-g02){#F2}

![Upper eyelid crease incision revealed a smooth, encapsulated mass (arrow) under a whitish, mildly swollen lacrimal gland (arrowhead).](cop-0007-0398-g03){#F3}

![Dispersion of oval to spindle-shaped cells in a heavily collagenized stroma with staghorn vessels (arrow), consistent with a SFT. **a** Hematoxylin and eosin, ×40. **b** Hematoxylin and eosin, ×200. **c** CD34 (original magnification ×400). **d** S-100 (original magnification ×400).](cop-0007-0398-g04){#F4}

###### 

Clinical findings of SFT in the lacrimal fossa

  Case No.   Age/sex   Clinical presentation                                  Follow-up            Reference
  ---------- --------- ------------------------------------------------------ -------------------- -----------------------------------
  1          76/M      ptosis, proptosis                                      NED 1 year           Scott et al. \[[@B2]\], 1996
  2          24/M      palpable mass, swelling, proptosis                     NED 21 months        Kim et al. \[[@B3]\], 1999
  3          26/F      palpable mass, swelling, proptosis, diplopia, ptosis   NED 5 months         Kim et al. \[[@B3]\], 1999
  4          24/M      palpable mass                                          recurrence 4 years   Polito et al. \[[@B4]\], 2002
  5          37/M      proptosis                                              NED 3 months         Bernardini et al. \[[@B5]\], 2003
  6          NA        NA                                                     NA                   Furusato et al. \[[@B1]\], 2011
  7          NA        NA                                                     NA                   Furusato et al. \[[@B1]\], 2011
  8          39/M      palpable mass                                          NED                  Son et al. \[[@B6]\], 2013
  9          50/M      palpable mass, swelling                                NED                  Narang et al. \[[@B7]\], 2015
  10         25/F      palpable mass, proptosis                               NED 6 months         current case

NA = Not available; NED = no evidence of disease.
